Drug-coated balloons to treat fem-pop disease
April 27, 2014- Interviewed by Steven E. Greer, MD
At the Charing Cross symposium in London, Medtronic reported results of the IN-PACT trial of their paclitaxel balloon. 12-month patency rates were 82%, compared to angioplasty-alone rates of 52%.
We interviewed UCLA vascular surgeon Brian DeRubertis, M.D. to put the data in perspective. Bard also has a balloon-coated product.
Cardiology/interventional, UCLA Med Ctr, Vascular Surgery | apples49 | 
January 5, 2015 6:56 pm
No Comments
No comments yet.
Notice: comments_rss_link is deprecated since version 2.5! Use post_comments_feed_link() instead. in /data/30/1/121/80/1121895/user/1185656/htdocs/wordpress/wp-includes/functions.php on line 3406
RSS feed for comments on this post.
